Target choice and exon skipping regulate CRISPR-directed gene editing of NRF2 in head/neck and esophageal cancer cells.

Natalia Rivera-Torres, Lauren E Skelly, John A Rogowskyj, Guadalupe Aguilar, Kelly Banas, Pawel Bialk, Eric B Kmiec

Abstract read

In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Genotypic and Phenotypic Diversity as a Function of CRISPR-Directed Gene Knock-Out ofBiomolecules · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Natalia Rivera-TorresChristianaCare Gene Editing Institute, 550 South College Avenue, Newark, DE 19713, USA.

Lauren E SkellyChristianaCare Gene Editing Institute, 550 South College Avenue, Newark, DE 19713, USA.

John A RogowskyjChristianaCare Gene Editing Institute, 550 South College Avenue, Newark, DE 19713, USA.

Guadalupe AguilarChristianaCare Gene Editing Institute, 550 South College Avenue, Newark, DE 19713, USA.

Kelly BanasChristianaCare Gene Editing Institute, 550 South College Avenue, Newark, DE 19713, USA.

Pawel BialkChristianaCare Gene Editing Institute, 550 South College Avenue, Newark, DE 19713, USA.

Eric B KmiecChristianaCare Gene Editing Institute, 550 South College Avenue, Newark, DE 19713, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Head and neck cancer (HNC) is the seventh most diagnosed cancer, with a predicted 30% increase annually by 2030. Conventional treatment is often combinatorial involving chemotherapy and radiation therapy, immunotherapy, and surgery, but over time, therapy becomes ineffective as treatment resistance develops. Our laboratory has been advancing a CRISPR-directed gene editing platform as an augmentative therapeutic strategy for squamous cell carcinoma. Our genetic target is

Indexed as

cell therapychemosensitivityCRISPR-Cas9drug resistanceesophageal cancergene editinghead and neck cancerMT: Regular IssueNRF2precision oncologysquamous cell carcinomatranscription factor targeting

Identifiers

PMID41624405

DOI10.1016/j.omton.2025.201122

PMCPMC12856552

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.